Draft Guidance on Sumatriptan Succinate

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Sumatriptan succinate

Dosage Form; Route: Injectable; subcutaneous

Strengths:
- EQ 6 mg Base/0.5 mL
- EQ 4 mg Base/0.5 mL

Overview: The Reference (R) product is a drug-device combination product in which the drug constituent part consists of a parenteral solution and the device constituent part consists of an autoinjector. FDA recommends the following criteria be met for the proposed Test (T) product with respect to formulation and in vitro studies, in which case an in vivo Bioequivalence (BE) study will likely not be necessary.

Formulation: FDA recommends that the T formulation be qualitatively (Q1) and quantitatively (Q2) the same as the R formulation.

In Vitro Studies: FDA recommends that the following in vitro studies be conducted with the T and R autoinjectors containing sumatriptan succinate.

1. Type of study: Delivered Volume
   Design: The delivered volume test should be performed to determine the volume of fluid ejected out of the device.
   Equivalence based on: Population Bioequivalence (PBE) analysis of delivered volume.

2. Type of study: Ejection Time
   Design: The ejection time should be performed to determine the time to eject the volume of fluid out of the device.
   Equivalence based on: PBE analysis of ejection time.

3. Type of study: Trigger Force

---

1 See 21 CFR 3.2(e)(1).
2 Q1 (qualitative sameness) means that the T formulation uses the same inactive ingredient(s) as the R formulation.
3 Q2 (quantitative sameness) means that concentrations of the inactive ingredient(s) used in the T formulation are within ± 5% of those used in the R formulation.
4 Refer to the product specific guidance for Budesonide Inhalation Suspension for relevant principles regarding population bioequivalence (PBE) analysis procedures.
Design: The trigger force test should be performed to determine the force required to activate the device. 
Equivalence based on: PBE analysis of trigger force.

4. Type of study: Extended Needle Length 
   Design: The extended needle length test should be performed to determine the needle length that extends out of the device after ejection of the volume of fluid. 
   Equivalence based on: PBE analysis of extended needle length.

In certain circumstances, FDA may request information and/or comparative data including, but not limited to, the following: injection force, break loose force, extrusion force, needle bond strength, and needle deflection angle.

Additional Comments: FDA recommends that applicants conduct the above in vitro studies for both strengths of the T and R products. For each strength, use at least three batches each of the T and R products, with no fewer than 10 units from each batch. The three batches of the T product should be prepared from three different batches of the same critical device components. The T product should consist of the final device constituent part and final drug constituent formulation intended to be marketed. The manufacturing process for the T batches should be reflective of the manufacturing process to be utilized for the commercial batch. T and R products should be studied under the same instrumental conditions. Method validation should be performed using the R product, and the lot number(s) for the R products used for the validation should be provided. Applicants should provide all relevant standard procedures and validation data for each of the in vitro bioequivalence studies listed above.

Device: Applicants should refer to the FDA Guidance for Industry entitled, *Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA* (January 2017), which, when finalized, will provide the Agency’s current thinking on the identification and assessment of any differences in the design of the user interface for a proposed generic drug-device combination product when compared to its RLD.

FDA recommends that applicants consider the following characteristics of the R product in designing the T product:

- A single-dose, prefilled autoinjector device capable of delivering the same dose as the R product
- External operating principles and external critical design attributes
- Size and shape

In addition, in vitro studies should be conducted to support the functionality, accuracy, and robustness of the proposed T product.

---

5 Refer to the Guidance for Industry and FDA staff “Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products” (June 2013) for relevant principles regarding studies to support autoinjector devices.